Abstract Number: 2287 • 2017 ACR/ARHP Annual Meeting
Biosimilar Use in Children and Young People with Juvenile Idiopathic Arthritis in a Real-World Setting in the United Kingdom
Background/Purpose: Despite their increasing use in adults, there is little to no data available on the use of biosimilar drugs in children with JIA, despite…Abstract Number: 2288 • 2017 ACR/ARHP Annual Meeting
Successful Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR)
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA). It frequently has to be discontinued due to intolerance…Abstract Number: 2289 • 2017 ACR/ARHP Annual Meeting
Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes cohort (ReACCh-Out) showed a 45% chance of attaining inactive disease within a year of…Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…Abstract Number: 2291 • 2017 ACR/ARHP Annual Meeting
Three Treatment Strategies in Recent Onset DMARD Naive Juvenile Idiopathic Arthritis: First Results of Clinical Outcome after 24 Months
Background/Purpose: The BeSt treatment strategy for children with juvenile idiopathic arthritis (JIA) has not been determined. The aim of the BeSt for Kids study was…Abstract Number: 2292 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Common Treatment Strategies for Juvenile Arthritis in Usual Practice: Results from the Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort
Background/Purpose: The efficacy of medications in randomized trials may differ substantially from their effectiveness (degree of beneficial effect under “real world” clinical settings). Reliable estimates…Abstract Number: 2293 • 2017 ACR/ARHP Annual Meeting
Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis?
Background/Purpose: Identifying predictors for clinically inactive disease (CID) and sustained remission would allow rapid escalation of therapies for children less likely to achieve these states.…Abstract Number: 2294 • 2017 ACR/ARHP Annual Meeting
Utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network to Assess Practice Pattern Variation in Juvenile Idiopathic Arthritis
Background/Purpose: Despite modern treatment options for patients with juvenile idiopathic arthritis (JIA), rates of clinical inactive disease (CID) remain low. The Pediatric Rheumatology Care and…Abstract Number: 2295 • 2017 ACR/ARHP Annual Meeting
Methotrexate As First Line Therapy in Juvenile Idiopathic Arthritis-Associated Uveitis: Myth or Reality
Background/Purpose: Methotrexate (MTX) is the most used immunomodulatory drug in Juvenile Idiopathic Arthritis-associated uveitis (JIA-U) although its efficacy has been shown only in retrospective studies…Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…Abstract Number: 2297 • 2017 ACR/ARHP Annual Meeting
Golimumab Versus Tocilizumab in Uveitis Related to Refractory Juvenile Idiopathic Arthritis. National Multicenter Study of 33 Patients
Background/Purpose: Uveitis is a severe manifestation of Juvenil Idiopathic Arthritis (JIA). Systemic treatment is based on conventional immunosuppresants. Anti-TNFa are used in refractory cases, mainly…Abstract Number: 2298 • 2017 ACR/ARHP Annual Meeting
Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with onset before 16 years of age, that persists for at least 6 weeks, and has…Abstract Number: 2299 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Characteristics of Juvenile Idiopathic Arthritis-Associated Uveitis in Japan：the First Report from the Pediatric Rheumatology Association of Japan (PRAJ)
Background/Purpose: Several reports examined ethnic differences of Juvenile Idiopathic Arthritis -associated uveitis (JIA-U), however, there were no information from Japan. Therefore, PRAJ underwent multi-center surveillance…Abstract Number: 2300 • 2017 ACR/ARHP Annual Meeting
Predictive Value of Magnetic Resonance Imaging in Patients with Juvenile Idiopathic Arthritis in Clinical Remission
Background/Purpose: MRI studies on RA revealed that subclinical synovitis is common in patients in clinical remission and it is responsible for structural damage progression. MRI-detected…Abstract Number: 2301 • 2017 ACR/ARHP Annual Meeting
Assessing the Utility and Impact of Musculoskeletal Ultrasound in a Large Pediatric Rheumatology Clinic
Background/Purpose: Musculoskeletal ultrasound (MSUS) use in the care of pediatric rheumatology patients is increasing. Yet, despite the growing availability of MSUS, it remains unclear how…
ACR Meeting Abstracts